Mithramycin A

SKU: orb1741464

Description

Mithramycin A

Research Area

Cell Biology, Epigenetics & Chromatin

Key Properties

• CAS Number: 18378-89-7
• MW: 1085.15
• Purity: >98%
• Formula: C₅₂H₇₆O₂₄
• SMILES: [H][C@@]1(C[C@@H](O)[C@H](O)[C@@H](C)O1)O[C@@H]1C[C@]([H])(Oc2cc3cc4C[C@@]([H])([C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H](O[C@@]5([H])C[C@@H](O[C@@]6([H])C[C@@H](O[C@@]7([H])C[C@](C)(O)[C@H](O)[C@@H](C)O7)[C@@H](O)[C@@H](C)O6)[C@H](O)[C@@H](C)O5)C(=O)c4c(O)c3c(O)c2C)O[C@H](C)[C@H]1O
• Target: Methyltransferase
• Solubility: Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 10 mg/ml).

Bioactivity

• In Vivo:
  The antitumor activity of Mithramycin A (0.2mg/kg/day) was measured in a xenograft model and the reduction in tumor volume and weight was observed. No significant weight loss was observed in mice treated with Mithramycin A, suggesting that Mithramycin A-associated toxicity was minimal. Mithramycin A also increased TUNEL positive cells in tumor xenografts. No significant intergroup differences were observed in the organs, suggesting no significant signs of systemic toxicity at the dose of Mithramycin A used in this study .
• In Vitro:
  Mithramycin A decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. Mithramycin A inhibits HEp-2 (50, 100, 200nM) and KB cell (20, 40, 80nM) growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Mithramycin A leads to significant DNA fragmentation compared to untreated controls .

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

A2371; Antibiotic LA 7017; Aureolic Acid; NSC 24559; PA 144; Plicamycin

Compound Identifiers

PubChem CID

163659